The Netherlands

Fastned, the Dutch operator of charging stations for electric cars, has raised €150m to finance an expansion of its network across Europe, at the end of a wild week for tech and green energy stocks.

BNP Paribas returned to the Swiss franc market to land a new senior non-preferred issue slightly inside its euro curve this week. In recent weeks, several foreign borrowers have tapped the market and, with tightening levels looking attractive, bankers are confident more could follow.

NN Bank took advantage of rising yields to issue a 20 year covered bond on Tuesday which was priced inside fair value.

An undisclosed pre-IPO shareholder sold €935m of shares in Adyen on Monday, after the Dutch payment company’s share price reached an all-time high last week following its 2020 results announcement. But a run on tech stocks saw the shares’ price quickly drop.

Bank Nederlandse Gemeenten hit the market for a sterling trade on Monday, securing its cross-currency swap hedge in advance to minimise volatility.

NN Bank has mandated leads for a 20 year covered bond amid improved hopes of an increase in supply, as banks emerge from blackout to take advantage of the recent rise in yields.

Universal Music, the international music company owned by Vivendi, will be spun off on the Amsterdam stock exchange, with the French firm distributing around 60% of the company to its shareholders.

ESG Core Investments has become the first European special purpose acquisition company to go public in 2021.

A pair of triple-A rated European agencies sold their first Swiss franc bonds for several years this week, responding to reverse enquiry for long dated, high rated paper.

Achmea has become the latest Dutch bank to transition to a soft bullet maturity. This will have a material impact on central bank treatment and funding, but opportunities to extract value in the secondary market will be a challenge.

A Dutch shell company is vying to become the first European special purpose acquisition company (Spac) to list this year.

Dutch biotech firm argenx has tapped equity investors for $1bn (€830.3m) to finance research and development.